Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy-Reference-Cited by-同舟云学术

Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy

Published:2024-01 Issue:1 Volume:12 Page:199-215
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Coats Caroline J.,Maron Martin S.,Abraham Theodore P.,Olivotto Iacopo,Lee Matthew M.Y.,Arad Michael,Cardim Nuno,Ma Chang-Sheng,Choudhury Lubna,Düngen Hans-Dirk,Garcia-Pavia Pablo^ORCID,Hagège Albert A.,Lewis Gregory D.,Michels Michelle,Oreziak Artur^ORCID,Owens Anjali T.,Tfelt-Hansen Jacob,Veselka Josef,Watkins Hugh C.,Heitner Stephen B.,Jacoby Daniel L.,Kupfer Stuart,Malik Fady I.,Meng Lisa,Wohltman Amy,Masri Ahmad

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference61 articles.

1. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy;Richard;Circulation,2003

2. Molecular genetic basis of hypertrophic cardiomyopathy;Marian;Circ Res,2021

3. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1;Jarcho;N Engl J Med,1989

4. Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light;Trivedi;Biophys Rev,2018

5. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Ommen;J Am Coll Cardiol,2020

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aficamten and Cardiopulmonary Exercise Test Performance;JAMA Cardiology;2024-09-04

2. Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy;Journal of the American College of Cardiology;2024-09

3. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy;Journal of the American College of Cardiology;2024-09

4. Novel cardiac myosin inhibitor for hypertrophic cardiomyopathy;Journal of General Physiology;2024-08-12

5. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM;Journal of the American Heart Association;2024-08-06